CClinicalTrials.gg
TerminatedNCT05343143Updated May 16, 2024

NeuraGen 3D Pilot Study

An interventional study of NeuraGen 3D Nerve Guide Matrix in Digital Nerve Injury, sponsored by Integra LifeSciences Corporation. Terminated at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Integra LifeSciences Corporation · Not applicable, Interventional, and Treatment

Why this study was terminated
Slow Enrollment, Sponsor Decision

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 2 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a 10-subject, 12-month follow-up, prospective, multi-center, open-label, single arm clinical trial designed to understand the initial performance characteristics and confirm the safety profile of the NeuraGen 3D Nerve Guide Matrix.

Read the detailed description

The NeuraGen® 3D Nerve Guide Matrix is indicated for the repair of peripheral nerve discontinuities where tension-free closure can be achieved by flexion of the digit or extremity.

02

Conditions studied

  • Digital Nerve Injury
03

In context

Lead sponsor

Integra LifeSciences Corporation is the lead sponsor of 81 studies on the registry; 5 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subject has one, single level, digital nerve injury that:
  • Involves complete traumatic nerve section of the common or proper nerve of the palmar aspect of hand.
  • Occurred less than and up to 21 days prior to the nerve repair surgery detailed in this protocol.
  • In the opinion of the investigator, has a gap which can be easily closed without placing undue tension on the ends of the nerves with the device (i.e., the gap must be shorter than the maximum length of the device being used).
  • Subject has adequate vascular perfusion of the target hand as assessed by the investigator
  • Subject can accommodate immobilization of the injured hand post-operatively.
  • Subject's contralateral hand is intact and of normal function.

Exclusion Criteria:

  • Nerve to be repaired is a mixed motor nerve
  • Subject has a known history of hypersensitivity to bovine-derived or chondroitin-based materials.
  • Subject's hand injury is of a nature which could negatively impact healing of the target nerves such as a crush or avulsion injury, incomplete transection of the target nerve, or complete separation of the digit affiliated with the target nerve.
  • Subject's hand injury or general physical presentation of the target hand is of a nature which would prevent adequate measurement of functional nerve healing assessments.
  • Subject has gross contamination of the wound in which the nerve to be studied in this protocol resides (i.e., presence of glass, metal, other large debris).
  • Subject has pre-existing nerve lesions or known diagnosis of compressive neuropathy of median or ulnar nerves (i.e., Cubital or carpal tunnel syndrome).
  • Subject has an active infection of the area around the nerve defect.
  • Subject has unstable vital signs.
  • Subject has a disorder known to affect the peripheral nervous system (PNS) such as:
  • Subject has any systemic disease which may confound study results Subject is known to have received immunosuppressive or antineoplastic agents or systemic steroids within 7 days of the study.
  • Subject is known to have had or will require radiation or other therapy to the target hand or limb which may impact nerve healing.
  • Subject has a history of injury to or a congenital abnormality of the target hand or limb which may impact nerve healing or confound study results.
  • Subject is pregnant (determined either by the subject's confirmation or a formal test).
  • Subject has participated in another clinical trial using an investigational drug or device within 30 days prior to the nerve repair surgery detailed in this protocol.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Other
    NeuraGen 3D Nerve Guide Matrix

    Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.

    Device: NeuraGen 3D Nerve Guide Matrix

Interventions

  • DeviceNeuraGen 3D Nerve Guide Matrix

    Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to evaluate return to sensory recovery with the NeuraGen 3D Nerve Guide Matrix in a small group of subjects with primary nerve injury of the hand.(s2PD) at each post-operative timepoint of the study.

    To be assessed during in office visits using the DeMayo 2-point discrimination device

    Time frame: 12 Months

Secondary outcomes

  1. Moving 2 Point Discrimination Test (m2PD) at each post-operative timepoint of the study:

    To be assessed during in office visits using the DeMayo 2-point discrimination device

    Time frame: 12 Months

  2. Grip Strength Test at each post-operative timepoint of the study

    To be assessed during in office visits using the Camry hand dynamometer

    Time frame: 12 Months

  3. Pinch Strength Test at each post-operative timepoint of the study

    To be assessed during in office visits using the Baseline Digital Pinch Gauge

    Time frame: 12 Months

  4. Semmes-Weinstein Monofilament Testing at each post-operative timepoint of the study

    To be assessed during in office visits using the Baseline Tactile Semmes-Weinstein monofilament

    Time frame: 12 Months

  5. Disabilities of the Arm, Shoulder and Hand (DASH) Score at each post-operative timepoint of the study

    To be completed via in office visits

    Time frame: 12 Months

  6. Michigan Hand Outcomes Questionnaire (MHQ) at each post-operative timepoint of the study

    To be completed via in office visits

    Time frame: 12 Months

  7. Continuous Visual Analog Scale for Pain at each post-operative timepoint of the study

    0-100 Scale, 0-no pain at all, 100- worst possible pain. To be completed via in office visits

    Time frame: 12 Months

07

Study locations

4 sites
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Duke University
    Durham, North Carolina 27708, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15261, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05343143
Lead sponsor
Integra LifeSciences Corporation
Responsible party
Sponsor
First posted
Apr 25, 2022
Start date
May 15, 2022
Primary completion
Jul 11, 2023
Completion
May 13, 2024
Last update
May 16, 2024

Study contacts

Maria Leonard
study director · Integra LifeSciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion